Cholestatic Pruritus Associated with PBC: Understanding Unmet Patient Needs and Treatment Strategies

Interprofessional Patient Case

Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team. They also explore safety and efficacy data from trials of emerging treatment options including ileal bile acid transporter (IBAT) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists.

Investigational Therapies

Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team. They also explore safety and efficacy data from trials of emerging treatment options including ileal bile acid transporter (IBAT) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists.

Current Treatment Options

Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team. They also explore safety and efficacy data from trials of emerging treatment options including ileal bile acid transporter (IBAT) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists.

Treatment Overview

Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team. They also explore safety and efficacy data from trials of emerging treatment options including ileal bile acid transporter (IBAT) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists.

Diagnosis and Monitoring

Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team. They also explore safety and efficacy data from trials of emerging treatment options including ileal bile acid transporter (IBAT) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists.